Related Experiment Videos
Milrinone therapy in catecholamine-dependent critically ill patients with heart failure
P Siostrzonek1, M Koreny, G Delle-Karth
1Department of Cardiology, University Clinic of Vienna, Austria.
Acta Anaesthesiologica Scandinavica
|April 11, 2000
Summary
Milrinone improves hemodynamics and aids in weaning patients off catecholamine therapy for heart failure. This treatment is safe for critically ill patients, though it may increase the need for vasoconstrictors and fluids.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure management often involves catecholamine therapy.
- Prolonged catecholamine use presents challenges in weaning patients.
- Milrinone, a PDE-III inhibitor, is known to improve hemodynamics.
Purpose of the Study:
- To evaluate the safety and efficacy of milrinone in critically ill patients with catecholamine-dependent heart failure.
- To determine if milrinone facilitates weaning from prolonged catecholamine therapy.
Main Methods:
- A randomized study involving 20 adult patients with heart failure and prolonged catecholamine therapy.
- Patients were assigned to either milrinone addition or continued catecholamine therapy.
- Hemodynamic parameters, fluid intake, and catecholamine doses were monitored.
Main Results:
- Milrinone significantly increased cardiac index and decreased systemic vascular resistance.
- Patients receiving milrinone required lower doses of dobutamine.
- Milrinone treatment was associated with higher rates of successful catecholamine weaning and improved survival from the ICU.
Conclusions:
- Milrinone improves central hemodynamics in critically ill heart failure patients.
- Milrinone can facilitate weaning from prolonged catecholamine support.
- While safe, milrinone administration may necessitate increased vasoconstrictor and fluid support.